What did the semaglutide weight loss trials actually find?

What exactly did the STEP trials test, and who was in them?

The STEP (Semaglutide Treatment Effect in People with obesity) programme comprised several parallel trials designed to answer different questions about once-weekly semaglutide 2.4mg. STEP 1 is the headline study: 1,961 adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition, none of whom had type 2 diabetes. Half received semaglutide 2.4mg weekly; half received a placebo. All participants also took part in a lifestyle intervention involving dietary guidance and increased physical activity.

That last detail matters. The trials were not testing the injection in isolation, they were testing it as part of a structured programme, which is exactly how semaglutide is licensed for use in the UK. Participants started at 0.25mg and titrated upward roughly every four weeks, reaching the 2.4mg maintenance dose by week 16. If you want to understand more about how the semaglutide trial was structured before deciding whether treatment is right for you, our dedicated overview walks through the key details. The 68-week duration was chosen to capture sustained weight loss rather than an early drop followed by a plateau.

STEP 2 enrolled adults with type 2 diabetes and reported average losses of around 10%, meaningful, but lower than STEP 1. STEP 3 added intensive behavioural therapy on top of the injection; STEP 4 looked at what happens when you stop, finding significant weight regain when the medicine is withdrawn. Taken together, the programme gave regulators and NICE a detailed picture of how the treatment behaves across different populations and conditions.

What were the actual results, and how should you read them?

A question our prescribers hear most weeks: "I read I could lose 15%, is that guaranteed?" The short answer is no, and understanding why is useful. The 15% figure from the Wegovy trial is an average across all participants who completed STEP 1 on semaglutide. Some lost considerably more; some lost less. Averages smooth that variation out.

Roughly two-thirds of participants in STEP 1 lost at least 10% of their starting weight. About a third lost 20% or more. The placebo group, who also received lifestyle support, lost an average of around 2.4%. The gap between those two numbers (roughly 12.5 percentage points) is the medicine's own contribution, over and above what structured lifestyle change alone produced in that trial context.

You can read the full STEP 1 paper through the New England Journal of Medicine; the methodology and confidence intervals are there in full for anyone who wants to dig into the statistical detail. The practical takeaway: the evidence is robust, the results are real, and individual outcomes still vary. That is not a caveat to dismiss, it is the reason clinical assessment exists.

For a broader look at how semaglutide performs for weight loss outside the trial context, including what happens in real-world use, our overview covers the current picture.

How did trial eligibility translate into the UK licence and NICE guidance?

Regulators use trial data to set the boundaries of a medicine's licence. The MHRA approved Wegovy for adults with a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition, hypertension, high cholesterol, obstructive sleep apnoea, and type 2 diabetes are among the qualifying conditions. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance.

NICE went further in specifying NHS access. Its appraisal of semaglutide (TA875) recommends it for use within specialist weight management services, for a maximum of two years, and for adults meeting specific BMI and comorbidity thresholds. That is a narrower gate than the licence itself, which is why many people who are eligible under the licensed criteria do not currently qualify for NHS treatment, or face long waits when they do. NICE's full appraisal of semaglutide (TA875) sets out the NHS criteria in detail.

Private prescribing follows the licensed indication rather than the NICE NHS criteria, which is one reason private routes exist for people who meet the clinical threshold but are outside the current NHS cohorts. Either way, a prescriber still needs to assess you individually, the trial results tell us what the medicine can do across a population; they do not tell a clinician whether it is right for a specific person.

If you are weighing up the cost of private Wegovy in the UK, understanding what the clinical process involves helps make sense of why prices vary between providers.

What side effects did the trials record, and how serious were they?

The STEP programme was large enough to give a clear picture of the side-effect profile. Gastrointestinal effects were the most common: nausea, vomiting, diarrhoea, constipation, and indigestion. These were typically most noticeable at the start of treatment or after a dose increase, and most participants found them manageable or saw them settle within a few weeks.

More serious events were uncommon but documented. Gallbladder-related problems occurred at a higher rate in the semaglutide group than in placebo. Acute pancreatitis is listed as a known but infrequent risk; the MHRA highlighted this in a safety communication in January 2026 and advises patients to seek urgent medical help for severe, persistent stomach pain that radiates to the back. That guidance applies to all GLP-1 medicines, including semaglutide.

The trials excluded people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, that exclusion is reflected in the licence. Semaglutide is not recommended during pregnancy, whilst breastfeeding, or for those actively trying to conceive. The NHS medicines information page for semaglutide gives a plain-language summary of the full side-effect and contraindication picture, and is worth reading alongside any clinical assessment. If you have questions about a specific medication you already take, interactions with antidepressants like citalopram are covered separately.

Ready to understand whether the trial evidence applies to your situation? Check your eligibility with our prescribers, the consultation is free, and a real clinician reads every response the same day.